Table_1.xls (5.5 kB)
Summary of Bliss scores and sensitivity to dinaciclib, navitoclax and combination treatment.
dataset
posted on 2014-10-07, 03:18 authored by Robert N. Booher, Harold Hatch, Brian M. Dolinski, Thi Nguyen, Lauren Harmonay, Ali-Samer Al-Assaad, Mark Ayers, Michael Nebozhyn, Andrey Loboda, Heather A. Hirsch, Theresa Zhang, Bin Shi, Carrie E. Merkel, Minilik H. Angagaw, Yaolin Wang, Brian J. Long, Xianlu Q. Lennon, Nathan Miselis, Vincenzo Pucci, James W. Monahan, Junghoon Lee, Anna Georgieva Kondic, Eun Kyung Im, David Mauro, Rebecca Blanchard, Gary Gilliland, Stephen E. Fawell, Leigh Zawel, Alwin G. Schuller, Peter Strack1
Synergy analysis after 18 hr treatment. vBliss: synergy (>0.1), additive (0.1–0.05). neutral (<0.05-0), antagonistic (<0).
2Percent viability after 18 hour treatment with 100 nM dinaciclib, 1 µM navitoclax or the combination.
3Information source. Cancer Cell Line Encyclopedia converted from log 2 to log10.
Summary of Bliss scores and sensitivity to dinaciclib, navitoclax and combination treatment.
